ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs based on two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for the
CEO Stephen C. Glover to discuss important development status updates of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for kidney disease and Inflammasome ASC
As remote work becomes a permanent fixture of American employment, a new national study from John Foy & Associates uncovers the rising dangers hiding behind
A groundbreaking new analysis from High Rise Financial highlights a severe and escalating crisis inside U.S. nursing homes, where tens of thousands of elderly residents
Under Florida’s no-fault system, your PIP pays medical bills (typically 80%) and lost wages (about 60%) after a crash, regardless of fault, but prompt action is crucial. Get treatment within
injuredly News Provide the latest news. All News World News, Business News, Health Care, Life Style. All News Around the World Update On This Website.